TAVI and PCI: redefining treatment for aortic stenosis and complex coronary artery disease

Affiliations

¹ Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova Medical School, 35128 Padova, Italy. Electronic address: giuseppe.tarantini.1@gmail.com.
² Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova Medical School, 35128 Padova, Italy.

Comment

Giuseppe Tarantini et al. Lancet. 2025.

. 2025 Dec 21;404(10471):2492-2493.

doi: 10.1016/S0140-6736(24)02318-3. Epub 2024 Dec 4.

¹ Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova Medical School, 35128 Padova, Italy. Electronic address: giuseppe.tarantini.1@gmail.com.
² Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova Medical School, 35128 Padova, Italy.

No abstract available

Conflict of interest statement

GT reports lecture fees from Abbott, Edwards Lifesciences, Medtronic, Microport, GADA, and Abiomed. FC declares no competing interests.

TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and complex or multivessel coronary disease (TCW): an international, multicentre, prospective, open-label, non-inferiority, randomised controlled trial.
Kedhi E, Hermanides RS, Dambrink JE, Singh SK, Ten Berg JM, van Ginkel D, Hudec M, Amoroso G, Amat-Santos IJ, Andreas M, Campante Teles R, Bonnet G, Van Belle E, Conradi L, van Garsse L, Wojakowski W, Voudris V, Sacha J, Cervinka P, Lipsic E, Somi S, Nombela-Franco L, Postma S, Piayda K, De Luca G, Kolkman E, Malinowski KP, Modine T; TCW study group. Kedhi E, et al. Lancet. 2025 Dec 21;404(10471):2593-2602. doi: 10.1016/S0140-6736(24)02100-7. Epub 2024 Dec 4. Lancet. 2025. PMID: 39644913 Clinical Trial.